Sunil Verma

Summary

Affiliation: Sunnybrook Health Sciences Centre
Country: Canada

Publications

  1. ncbi request reprint Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane
    Sunil Verma
    Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Am J Clin Oncol 30:297-302. 2007
  2. pmc Treatment of locally advanced breast cancer
    Sunil Verma
    CMAJ 171:219; author reply 221-2. 2004
  3. doi request reprint Anthracyclines in early-stage breast cancer: is it the end of an era?
    Danny Robson
    Sunnybrook Odette Cancer Centre, Toronto, Ontario M2N3E6, Canada
    Oncologist 14:950-8. 2009
  4. pmc In the end what matters most? A review of clinical endpoints in advanced breast cancer
    Sunil Verma
    University of Toronto, Sunnybrook Odette Cancer Centre, T Wing, 2nd Floor, 2075 Bayview Avenue, Toronto, Ontario, M2N 3E6, Canada
    Oncologist 16:25-35. 2011
  5. doi request reprint Trastuzumab emtansine for HER2-positive advanced breast cancer
    Sunil Verma
    Sunnybrook Odette Cancer Centre, Toronto, ON M4N 3M5, Canada
    N Engl J Med 367:1783-91. 2012
  6. doi request reprint Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer?
    S Verma
    Department of Medicine, Sunnybrook Odette Cancer Centre, Toronto, Canada
    Ann Oncol 22:1011-8. 2011
  7. ncbi request reprint First-line treatment options for patients with HER-2 negative metastatic breast cancer: the impact of modern adjuvant chemotherapy
    Sunil Verma
    Division of Medical Oncology, Sunnybrook and Women s College Health Sciences Centre, T Wing, 2nd Floor, TSRCC, Toronto, ON, Canada
    Oncologist 12:785-97. 2007
  8. ncbi request reprint The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy
    Mark Vincent
    London Regional Cancer Program, 790 Commissioners Road E, London, ON, N6A 4L6, Canada
    Support Care Cancer 15:265-72. 2007
  9. doi request reprint Quantitative ultrasound evaluation of tumor cell death response in locally advanced breast cancer patients to chemotherapy treatment administration
    Gregory Czarnota
    Imaging Res and Radiation Oncology, Sunnybrook Health Sci Ctr, 2075 Bayview Ave, Toronto, ON M4N 3M5
    J Acoust Soc Am 133:3539. 2013
  10. pmc Review of the clinical studies using the 21-gene assay
    Catherine M Kelly
    Division of Medical Oncology, Sunnybrook Odette Cancer Centre, The University of Toronto, Toronto, Ontario, Canada, M4N 3M5
    Oncologist 15:447-56. 2010

Collaborators

Detail Information

Publications27

  1. ncbi request reprint Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane
    Sunil Verma
    Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Am J Clin Oncol 30:297-302. 2007
    ..Common therapeutic alternatives include capecitabine and vinorelbine. This retrospective chart review compares overall survival following treatment with capecitabine, vinorelbine, or both agents sequentially in this group of women...
  2. pmc Treatment of locally advanced breast cancer
    Sunil Verma
    CMAJ 171:219; author reply 221-2. 2004
  3. doi request reprint Anthracyclines in early-stage breast cancer: is it the end of an era?
    Danny Robson
    Sunnybrook Odette Cancer Centre, Toronto, Ontario M2N3E6, Canada
    Oncologist 14:950-8. 2009
    ..With these new advances, the current role of anthracycline-based chemotherapy in early-stage breast cancer demands re-examination...
  4. pmc In the end what matters most? A review of clinical endpoints in advanced breast cancer
    Sunil Verma
    University of Toronto, Sunnybrook Odette Cancer Centre, T Wing, 2nd Floor, 2075 Bayview Avenue, Toronto, Ontario, M2N 3E6, Canada
    Oncologist 16:25-35. 2011
    ..In the end, what matters most is ensuring rapid access to safe and effective oncology treatments...
  5. doi request reprint Trastuzumab emtansine for HER2-positive advanced breast cancer
    Sunil Verma
    Sunnybrook Odette Cancer Centre, Toronto, ON M4N 3M5, Canada
    N Engl J Med 367:1783-91. 2012
    ..The antibody and the cytotoxic agent are conjugated by means of a stable linker...
  6. doi request reprint Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer?
    S Verma
    Department of Medicine, Sunnybrook Odette Cancer Centre, Toronto, Canada
    Ann Oncol 22:1011-8. 2011
    ..The duration of follow-up in many adjuvant studies may not be sufficient to determine the risk of late cardiac events. The findings indicate a need to study and standardize cardiac toxicity assessments in oncology trials...
  7. ncbi request reprint First-line treatment options for patients with HER-2 negative metastatic breast cancer: the impact of modern adjuvant chemotherapy
    Sunil Verma
    Division of Medical Oncology, Sunnybrook and Women s College Health Sciences Centre, T Wing, 2nd Floor, TSRCC, Toronto, ON, Canada
    Oncologist 12:785-97. 2007
    ....
  8. ncbi request reprint The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy
    Mark Vincent
    London Regional Cancer Program, 790 Commissioners Road E, London, ON, N6A 4L6, Canada
    Support Care Cancer 15:265-72. 2007
    ..e., a hemoglobin (Hb) of <or=100 g/l] in patients with advanced nonsmall cell lung cancer (NSCLC) receiving palliative chemotherapy is described...
  9. doi request reprint Quantitative ultrasound evaluation of tumor cell death response in locally advanced breast cancer patients to chemotherapy treatment administration
    Gregory Czarnota
    Imaging Res and Radiation Oncology, Sunnybrook Health Sci Ctr, 2075 Bayview Ave, Toronto, ON M4N 3M5
    J Acoust Soc Am 133:3539. 2013
    ..The results indicate that such responses can be detected early during a course of chemotherapy and should permit ineffective treatments to be changed to more efficacious ones potentially leading to improved treatment outcomes...
  10. pmc Review of the clinical studies using the 21-gene assay
    Catherine M Kelly
    Division of Medical Oncology, Sunnybrook Odette Cancer Centre, The University of Toronto, Toronto, Ontario, Canada, M4N 3M5
    Oncologist 15:447-56. 2010
    ..Better prognostic and predictive tests are needed. The 21-gene assay is the only widely commercially available gene signature that can be performed on formalin-fixed paraffin-embedded tissue...
  11. pmc The use of complementary and alternative medicines among patients with locally advanced breast cancer--a descriptive study
    Lucy K Helyer
    Department of Surgical Oncology, Toronto Sunnybrook Regional Cancer Centre, 2075 Bayview Ave, Toronto, ON, M4N 3M5, Canada
    BMC Cancer 6:39. 2006
    ..Complementary and alternative medicine (CAM) use is common among cancer patients. This paper reviews the use of CAM in a series of patients with locally advanced breast cancer (LABC)...
  12. ncbi request reprint Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy
    Mark J Clemons
    Division of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 24:4895-900. 2006
    ....
  13. pmc Impact of new chemotherapeutic and targeted agents on survival in stage IV non-small cell lung cancer
    Joanne L Yu
    Sunnybrook Odette Cancer Centre, T Wing 2nd Floor, 2075 Bayview Avenue, Toronto, Ontario, Canada, M4N 3M5
    Oncologist 16:1307-15. 2011
    ..This study examined uptake of these therapies in general practice and their impact on survival...
  14. ncbi request reprint Should oral bisphosphonates be standard of care in women with early breast cancer?
    Mark Clemons
    Division of Medical Oncology, Toronto Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    Breast Cancer Res Treat 90:315-8. 2005
    ..This article outlines the results of these studies and discusses the potential role for other bisphosphonates, such as ibandronate and zoledronic acid, in the adjuvant treatment of breast cancer...
  15. ncbi request reprint Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction model
    George Dranitsaris
    Toronto Sunnybrook Regional Cancer Centre, Ontario, Canada
    Lancet Oncol 6:856-63. 2005
    ..We aimed to develop a prediction model for anaemia in patients with breast cancer who were receiving adjuvant chemotherapy...
  16. doi request reprint Patient and physician perceptions on continuing aromatase inhibitors beyond the 5-year mark
    Sonal Gandhi
    Department of Medical Oncology, University of Toronto, and Toronto Sunnybrook Edmond Odette Cancer Centre, Toronto, Ontario, Canada
    Breast J 17:620-9. 2011
    ..Patients were willing to continue on AIs for smaller treatment benefits than physicians would prefer to prescribe them beyond 5 years. Patient preference to continue on AIs correlated somewhat to the severity of AI-related side effects...
  17. ncbi request reprint Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death
    Eileen Rakovitch
    Department of Radiation Oncology, Toronto Sunnybrook Regional Cancer Centre, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue, Ontario, Toronto, Canada, M4N 3M5
    Breast Cancer Res Treat 90:139-48. 2005
    ..The objective of this study is to assess the presence of anxiety and depression in breast cancer patients who use CAM and assess how they perceive their risks of recurrence and dying from breast cancer compared to non-users...
  18. ncbi request reprint Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian Medical Oncologists
    Sunil Verma
    Toronto Sunnybrook Regional Cancer Centre and Cancer Care Ontario, Toronto, Canada
    Support Care Cancer 12:852-8. 2004
    ..A questionnaire was therefore developed and administered to determine how medical oncologists in Canada use BPs in clinical practice...
  19. pmc Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer
    Daphne T Tsoi
    Division of Medical Oncology, Sunnybrook Odette Cancer Centre, The University of Toronto, Toronto, Ontario M4N 3M5, Canada
    Oncologist 15:457-65. 2010
    ..We evaluated the cost-effectiveness of recurrence score (RS)-guided treatment using 21-gene assay as compared with treatment guided by the Adjuvant! Online program (AOL)...
  20. ncbi request reprint Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter
    Sonal Gandhi
    University of Toronto, Toronto, ON, Canada
    Breast Cancer Res Treat 106:1-9. 2007
    ..It also highlights the importance of interpreting such data within the larger context of cardiovascular health in postmenopausal women...
  21. pmc Early breast cancer in the older woman
    Sonal Gandhi
    Department of Medical Oncology, Sunnybrook Odette Cancer Centre, Toronto, Canada
    Oncologist 16:479-85. 2011
    ..Women aged ≥65 are generally underrepresented in early breast cancer studies. Therefore, the optimal management of this group of women remains less certain...
  22. doi request reprint Quantitative ultrasound evaluation of tumor cell death response in locally advanced breast cancer patients receiving chemotherapy
    Ali Sadeghi-Naini
    Imaging Research Physical Science, Sunnybrook Research Institute, Toronto, Ontario, Canada
    Clin Cancer Res 19:2163-74. 2013
    ..This study investigates for the first time the potential of early detection of tumor cell death in response to clinical cancer therapy administration in patients using quantitative ultrasound spectroscopic methods...
  23. doi request reprint Primary care physicians' views of routine follow-up care of cancer survivors
    M Elisabeth Del Giudice
    Department of Family and Community Medicine, University of Toronto, Canada
    J Clin Oncol 27:3338-45. 2009
    ..However, current Canadian PCP views on this issue have been largely unknown...
  24. doi request reprint Oncology education in Canadian undergraduate and postgraduate training programs
    Winson Y Cheung
    Department of Medical Oncology, University of Toronto, Toronto, Canada
    J Cancer Educ 24:284-90. 2009
    ..We evaluated the quality of oncology education in undergraduate (UG) and postgraduate (PG) training programs...
  25. ncbi request reprint What is the best chemotherapy treatment option for anthracycline and taxane pretreated metastatic breast cancer?
    Sunil Verma
    J Clin Oncol 23:6260; author reply 6261. 2005
  26. ncbi request reprint Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials
    Federica Cuppone
    Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    Cancer 112:260-7. 2008
    ..0] was demonstrated...
  27. ncbi request reprint The lack of long-term effect of Cisplatin based combination chemotherapy on serum cholesterol for treatment of testicular cancer
    David W Fenton
    British Columbia Cancer Agency, Cross Cancer Institute, Edmonton, Alberta, Canada
    J Urol 168:1971-4. 2002
    ..We performed a cross-sectional study to assess further the relationship of cisplatin based chemotherapy and serum cholesterol in long-term survivors of testicular cancer...